Search
Clinical guidelines recommend genomic profiling to assess multiple biomarkers in routine practice in several advanced cancers to enable patient access to targeted therapies.
Next-generation sequencing (NGS) is a high-throughput sequencing technology that offers the advantage of simultaneous analysis of multiple targets from a single sample, providing comprehensive genomic profiles.
Enhancing patient care with NGS
In-house NGS allows for quicker turnaround times for genetic testing results, enabling faster diagnosis and timely intervention for patients. Additionally, it provides detailed genetic information that helps tailor personalized treatment plans based on the patient's unique genetic makeup.
Explore more:
Conserves samples by keeping them on site, helping to ensure they are readily available for any potential further testing.
Improves coordination of care in multidsciplinary teams and grows local expertise, helping to ensure comprehensive and collaborative patient management.
Cost of NGS versus total cancer care cost
It has been shown in an economic assessment of NGS testing workflows for NSCLC in a healthcare setting that NGS test constitutes only around 1% of the expenses incurred in their molecular diagnostic and therapeutic pathway. As the number of actionable biomarkers is increasing, the relative cost is even smaller.1
Learn from institutions with rapid NGS in house
Rapid NGS is enabling clinicians and reducing biomarker testing costs
In this recorded webinar, learn how the Massachusetts General Hospital (MGH) Center for Integrated Diagnostics (CID) has consolidated a legacy single-gene testing system into one workflow based on fast and automated NGS to produce a rapid lung molecular testing program.
View this webinar to:
- Learn from the experiences of a leading cancer center in consolidation of NSCLC biomarker testing into a Rapid Lung NGS program
- Understand the positive implications for oncologists and patients with cancer from the oncologist point of view
- Understand how the new consolidated workflow saves time and resources
Community-based Rapid NGS offers considerable advantages in clinical cancer care
In this free on‑demand webinar, Dr. Brandon Sheffield of Canada‑based William Osler Health System shares the organization's experience with implementing NGS in routine oncology biomarker testing.
In their pilot study, 578 solid tumor samples underwent genomic profiling. All testing was performed by one group of technologists within the same division of the laboratory, achieving a median turn‑around time (TAT) of three business days.
References:
1: Arriola E et al. (2023) Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers. JCO Precis Oncol 7:e2200546.
CN: 64505